LTA4H: A Potential Drug Target and Biomarker for Various Diseases

Target Name: LTA4H

NCBI ID: G4048

LTA4H

LTA4H: A Potential Drug Target and Biomarker for Various Diseases

LTA4H (LTAT4H) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Taoma family and belongs to the transferrin receptor (TPR) superfamily. The protein encoded by the LTA4H gene is a glycoprotein, which is a complex composed of sugar chains and proteins. In humans and other organisms, glycoproteins play important roles in cell signaling, metabolic regulation, immune response, and tumorigenesis.

The expression levels of LTA4H vary widely among different tissues and organisms. Expression levels of LTA4H are higher in neurons and lower in other tissues. This difference makes LTA4H a potential drug target.

As a drug target, LTA4H has high pharmacological value. Research shows that LTA4H can be used as a therapeutic target for Parkinson's disease. Parkinson's disease is a common neurodegenerative disease characterized by neuronal death and movement disorders. Currently, anti-Parkinson's drugs only relieve symptoms but do not cure the disease. Therefore, the development of new drug targets is of great clinical significance.

LTA4H can also serve as a therapeutic target for other diseases. For example, LTA4H can be used as a monitoring indicator of glycation end products (HbA1c) in patients with diabetes. HbA1c is an indicator of the glucose metabolism status of diabetic patients. The higher its value, the worse the patient's glucose metabolism status. Studies have shown that LTA4H can be used as a biomarker for monitoring glycation end products in patients with diabetes.

In addition, LTA4H can also be used as a biomarker for some tumors. For example, LTA4H can be used as a tumor marker for patients with tumors such as lung cancer, liver cancer, and breast cancer. Tumor markers in patients with these tumors can be used to monitor disease progression and treatment effectiveness.

The expression level of LTA4H can also be used as a prognostic indicator for certain diseases. For example, LTA4H can be used as a prognostic indicator in glomerulonephritis. Glomerulonephritis is a glomerular disease characterized by damage to the glomerular filtration membrane. Studies have shown that LTA4H can be used as a prognostic indicator for glomerulonephritis.

LTA4H also interacts with some medications. For example, the antihypertensive drug acetazolamide (Lisinopril) can reduce the expression level of LTA4H. This interaction suggests that LTA4H could serve as a target for antihypertensive drugs.

As a protein, LTA4H has broad application prospects in drug development and clinical applications. Future research can focus on the following aspects:

1. Drug target properties of LTA4H: Further study the biological functions of LTA4H, determine its drug target properties, and explore new drug targets.
2. Clinical application of LTA4H: Develop LTA4H as a therapeutic target for Parkinson's disease, diabetes, lung cancer and other diseases, and conduct clinical trials to evaluate its efficacy and safety.
3. Biomarker application of LTA4H: Use LTA4H as a biomarker for glucose metabolism, tumors and other diseases to conduct research on disease diagnosis, prognosis and treatment effect evaluation.
4. Study on the interaction of LTA4H: Study the interaction between LTA4H and other biomolecules to reveal its potential role in drug development and clinical application.

Protein Name: Leukotriene A4 Hydrolase

Functions: Bifunctional zinc metalloenzyme that comprises both epoxide hydrolase (EH) and aminopeptidase activities. Acts as an epoxide hydrolase to catalyze the conversion of LTA4 to the pro-inflammatory mediator leukotriene B4 (LTB4) (PubMed:11917124, PubMed:12207002, PubMed:15078870, PubMed:18804029, PubMed:1897988, PubMed:1975494, PubMed:2244921). Has also aminopeptidase activity, with high affinity for N-terminal arginines of various synthetic tripeptides (PubMed:20813919, PubMed:18804029). In addition to its pro-inflammatory EH activity, may also counteract inflammation by its aminopeptidase activity, which inactivates by cleavage another neutrophil attractant, the tripeptide Pro-Gly-Pro (PGP), a bioactive fragment of collagen generated by the action of matrix metalloproteinase-9 (MMP9) and prolylendopeptidase (PREPL) (PubMed:20813919, PubMed:24591641). Involved also in the biosynthesis of resolvin E1 and 18S-resolvin E1 from eicosapentaenoic acid, two lipid mediators that show potent anti-inflammatory and pro-resolving actions (PubMed:21206090)

The "LTA4H Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LTA4H comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets